When Cancer is Incurable

Patients and families face difficult decisions when the prognosis is poor, but communication and an action plan may help. 

Talk about this article with other patients, caregivers, and advocates in the Liver CURE discussion group.
For Dann Siems, the headaches began in early summer 2009, fishing season in northern Minnesota’s lake country. At first, aspirin worked. But during a trip later that summer to Lake of the Woods, nothing could cut the pain.

On a Monday in August, his family doctor saw the brain tumor in a scan. The next day, the doctor gave him the news. Before the end of the week, doctors in Fargo, N.D., performed a craniotomy to debulk the tumor and identify it. His diagnosis: high-grade glioblastoma, an aggressive malignancy. His prognosis: poor.

“Your life is just going along fine, and then suddenly everything is turned upside down, in just a few hours,” says Lenore Siems, who helped her husband deal with non-Hodgkin lymphoma five years before.

There’s no “typical” way that patients or families react to a diagnosis of incurable cancer, says Margaret Bevans, a clinical nurse scientist at the National Institutes of Health (NIH) Clinical Center in Bethesda, Md. “You need to give yourself space, time and the permission to be anything: sad, angry, frustrated, weepy.”

After absorbing the initial shock of diagnosis, reactions often differ greatly. Some patients decide to treat the cancer as aggressively as possible, hoping to extend survival or improve their quality of life. Others seek quality of life in other ways, declining treatments that are not likely to be curative to avoid side effects that may be uncomfortable or dangerous. Experts urge patients to respect their own needs and desires as they plan for the next weeks, months or years. “It’s not right or wrong to make any particular choice,” Bevans says. “It’s about being informed and making [those choices] personal.”

“Dann was very clear on what he wanted,” Siems says. “He wanted to try everything. But at the same time, he was realistic—more realistic than I was.”

An environmental biologist who was 51 at the time of his diagnosis, Dann Siems started talking with his wife about finances. “He didn’t want to put us in a hole with medical expenses because he knew it was highly likely that I was going to be a widow,” Siems says. In part, that’s why the couple began investigating clinical trials, she adds. “And part of it was Dann being a researcher. It was his legacy—to contribute some knowledge to society.”

I was always hopeful. In the back of my mind, it was always, 'Maybe this will be a cure.'

Through a colleague, the Siemses got in touch with an oncologist at the National Institutes of Health, who helped him enroll in several clinical trials and receive chemotherapy—nearly all for free.

“He was a bulldog,” Siems says of her husband. When a treatment stopped working, he’d call up experts in the field, researchers whose work he’d found online, to learn more. She says she sometimes struggled to keep up with the medical jargon. “We’d be meeting with the doctor, and they’d be in this big, animated discussion, and I would raise my hand and go, ‘Could you maybe say that in English?’”

Misunderstandings between doctors, patients and families are common, says Deborah Schrag, an associate professor of medicine at Harvard Medical School in Boston. Schrag recently co-authored a paper in which she and her colleagues assessed how well patients with advanced lung and colorectal cancers understood the likely effects of their chemotherapy. Many patients thought the treatment would probably cure their disease, although that was rarely true. Chemotherapy for advanced lung and colorectal cancers can alleviate symptoms and extend life in some patients by weeks or months but only rarely for more than several years.

“There are consequences [for] these misunderstandings,” Schrag says. “You can miss out on the ability to take charge and control of how you want to spend the rest of your life.”

Some people, she says, don’t seek that kind of control, but most eventually want to have a role in deciding how to spend the rest of their lives. “Should I repaint the bottom of the boat? Breed the dogs this spring?” Schrag says. “Should I spend Christmas with my daughter and son in California or wait?”

Individuals will answer those questions differently, depending on how they expect treatment to progress. “I have a patient who is going off to her granddaughter’s bat mitzvah before starting chemotherapy,” so she won’t be as sick during the celebration, Schrag says.

Doctors and patients need to work harder to ensure shared understanding, Schrag says. “A patient might ask to talk through the best scenario as well as the most likely,” for example, she says. “Because they can be different.”

“We were told they were not likely curative,” Siems says of her husband’s various chemotherapy regimens. “But I was always hopeful,” she adds. “In the back of my mind, it was always, ‘Maybe this will be a cure.’”

Bevans says she often talks with patients about “reframing” hope. Maybe it’s not for decades more of life, she says. “But there’s always hope for daily comfort and that each day you live your life well.”

Talk about this article with other patients, caregivers, and advocates in the Liver CURE discussion group.
Cure Connections
Related Articles
FDA Expands Opdivo Approval in Lung Cancer
The approval is based on data from the phase 3 CheckMate-057 trial, in which second-line Opdivo reduced the risk of death by 28 percent versus docetaxel in patients with nonsquamous NSCLC.
FDA Expands Optune's Glioblastoma Multiforme Indication
The approval was based on findings from the phase 3 EF-14 trial.
Pairing Radiation Oncology and Palliative Care Leads to Better Outcomes
A novel service model allowed for shorter durations of treatment with radiation, fewer unfinished treatments with radiation, shorter hospital stays and increased use of palliative care.
Keytruda Approved for Lung Cancer
The PD-1 inhibitor was approved along with a companion diagnostic, the PD-L1 IHC 22C3 pharmDx test, and is indicated for patients who progressed on or after platinum-containing chemotherapy or EGFR- or ALK-targeted agents in patients harboring those mutations.
The Other Shoe
The stage 4 lung cancer life twists and turns down a bumpy road, but it is a road that I am lucky enough to still be traveling.
Related Videos
Carolyn Presley on the Implications of Screening on Lung Cancer Care
Carolyn Presley discusses the implications of screening on diagnosis and treatment of lung cancer.
Carolyn Presley Discusses the Burden of Curative Lung Cancer Treatment
Carolyn Presley, clinical fellow, geriatric oncology, Yale Cancer Center, Robert Wood Johnson Clinical Scholar, discusses a study looking at the burden of health care on patients undergoing curative lung cancer care.
Lecia V. Sequist on Side Effects From Agents for Resistant Lung Cancer
Lecia V. Sequist, discusses the adverse event profiles of rociletinib (CO-1686) and osimertinib (AZD9291).
Lecia V. Sequist Provides an Overview of T790M Mutations in NSCLC
Lecia V. Sequist, associate professor of medicine, Massachusetts General Hospital, provides an overview of T790M, a mutation in the epidermal growth factor receptor (EGFR) gene.
Marianne Davies on Immunotherapy-Related Side Effects in Lung Cancer
Marianne Davies, from Smilow Cancer Hospital, Yale School of Nursing, provides an overview of immunotherapy-related side effects that patient with lung cancer may experience.